ASCO 2024

The search for predicitve biomarkers continues

Immunotherapy makes a difference in survival in eTNBC

Adjuvant endocrine therapy for ER-low EBC

Personalized neoadjuvant therapy for high-risk breast…

AI for the prediction of disease progression

ctDNA analysis in monarchE

Advantage for node-negative patients

ctDNA important for HR+ eBC?

One step closer to chemo-free therapy for HR+/HER2+…

Reassuring and clarifying new data for CDK4/6…

Expanding T-DxD use to HER2 ultra-low - the success…

Triple positive mBC - chemotherapy unnecessary?

New data on the omission of chemotherapy in young…

ER-low: endocrine therapy necessary after all?

Heterogenity of ER+ disease

Systemic therapy of HER2+ patients with brain…

Responder premenopausal

Is there still a place for endocrine therapy in HER2+…

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Broaden T-DXD as therapy standard for HER2low and…

Ultra low - ultra good?

Important OS benefit with T-Dxd in HER2+ mBC

HER2+ mBC 1stL T-Dxd

T-DXD continues its impressive track record for MBC…

Sacituzumab tirumotecan - a new powerful ADC for…

Decreasing SG related toxicity with profilatic G-CFS

The ADC revolution continues - ctDNA takes the next…

Novel ADC-ICI combination therapy

CDK4/6 rechallenge

INAVO120 - updated results

CDK4/6i effective in premenopausal patients as well

First-line inavolisib/placebo + palbociclib +…

Chemo-free, CDK4/6 inhibitor-based combination active…

Endocrine therapy with Palbociclib + Trastuzumab

Already more in the 1stL?

Treatment beyond progression for CDK 4/6i

Espansione dell'uso di T-DxD nelle pazienti con…

C'è ancora posto per la terapia endocrina nel BC HER2+?

CDK4/6 rechallenge

INAVO120: risultati aggiornati

Regime senza chemioterapia nel carcinoma mammario…

Sacituzumab tirumotecan – nowy aktywny koniugat w…

La révolution de l'ADC se poursuit / ctDNA franchit une…

Disminución de la toxicidad relacionada con la OS con…

Le traitement endocrinien a-t-il encore sa place dans…

Importante beneficio en la supervivencia global con…

PSMA-PET CT: Ready for clinical practice or a PROMISE…

Interesting data - but not practice changing

Is the metformin story over? How to treat HFNS…

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

Exploring the CHAARTED TRIAL: Optimizing Treatment…

mCRPC: Who benefits from which measures?

Important QoL data

mCRCP CYCLONE 2 study

Radionukleotides - the next step forward

The evolving role of PSMA-PET with new agents

EMBARK: Quality of Life

Unveiling the Potential: PSMA-PET in Prostate Cancer…

ARASENS Post hoc analysis: Therapy after progression

RCT in mCRPC

EMBARK demonstrates the importance of HRQoL benefit in…

Perioperative treamtent in MIBC - new data for the use…

Quality of life not affected by i. v. Pembro

ctDNA as a biomarker in metastatic bladder cancer

ASCO 2024: Time for the rare GU tumors?

Modified FOLFIRINOX therapy as a good option for…

Biomarkers and long-term outcomes in pts with low tumor…

Effect of an immune diet on the outcome after radical…

Treatment of urachal carcinoma

What to do with Cis Gem Nivo?

MI-UC - News from EVP standard

Interim analysis of the SURE-01/02 study

ASCO24: Bladder cancer highlights

The future of sacituzumab govitecan

ASCO 2024: momento para los tumores GU poco frequentes?

El papel de los inhibidores de topoisomerasa en el…

ASCO24: Bladder cancer highlights

El futuro de sacituzumab govitecan

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms…

Advancing Our Understanding of Biological Mechanisms…

Combination is superior to monotherapy - how do we…

The never ending saga of biomarkers

Adjuvant KIM-1 as prognostic & predictive biomarker

New HIF inhibitor in clear cell RCC

Metastasized chromophobe RCC

Biomarker analysis of KN426 & CLEAR

KIM-1 - old wine in new bottles

NIVO+CABO: significantly longer therapy-free time

Belzutifan in earlier lines in advanced ccRCC

nccRCC

DFF332 a novel HIF inhibitor

KIM-1: Will have a major impact

The search of the ideal biomarker in advanced renal…

Treatment of favorable prognosis mRCC patients:…

Another breakthrough perioperative

New IMDC risk group - very favorable

Tratamiento del cancer renal avanzado de pronostico…

End of the story in EGFRm disease?

Osimertinib improves PFS in stage III

Confirmed efficacy of periop IO in N2 R-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

Gamechanger in EGFR-mutated NSCLC

4-year efficacy of Keynote-799 and ctDNA

Early change in SOC in EGFR+ LD-NSCLC

ctDNA predicts outcome in patients treated with…

CheckMate 816: 4-year update

4y follow-up of CheckMate 816

Liquid biopsy in curative situation

4y follow-up de CheckMate 816

Le traitement adjuvant par osimertinib apres CTRT : …

TROP2-targeting ADCs: where a we heading?

Lorlatinib with extraordinary data in ALK + NSCLC

KRAS in NSCLC - a lot to come

EGFR+ NSCLC - amivantamab-based combination therapy

The end for local therapy for oligometastatic disease

Subcut amivantamab - the future

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

Lorlatinib convincing in ALK mutation 1st line

BAY2927088 - Promising Her2-Inhibitor in NSCLC

Adagrasib for KRASG12C mutation 2nd line

KRAS building on single agent therapy

KRASG12C - the story continues

ADCs - moving landscapes. Subgroups remain to be…

Telehealth is just as effective as a face-to-face visit…

Confirmed efficacy of adagrasib in KRASG12C

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

Het einde van lokale therapie voor oligometastatische…

ASCO 2024 highlights

KRASG12C - het verhaal gaat verder

La télésanté est aussi efficace qu'une consultation…

Finally, change for LS-SCLC

New SoC for LD-SCLC

LD-SCLC: What´s about PCI?

Maintenance with durvalumab is the new SOC after…

Le traitement d'entretien avec le durvalumab est le…

Harsh to beat

Personalized mRNA-vaccination: Practice changer of the…

Is adjuvant treatment still standard in macroscopic,…

10 years follow up - immunotherapy for BRAF-mutated…

Is the triplet ready for phase 3?

Stimulating new combination of two antibody-cytokine…

Progress in neoadjuvant therapy with IO

Promising activity of brenetafusp in PD-L1 refractory…

Promising Results: Triple combination therapy in…

Impactful studies from ASCO 24 II: Combi-AD

mRNA vaccine plus pembrolizumab in adjuvant therapy

Adjuvant therapy with dabrafenib and trametinib - final…

Vaccine in combination with nivolumab for PDL1…

Impactful studies from ASCO 24 I: NADINA

Consolidation of the use of IO in clinically detectable…

3-year update on mRNA vaccines in melanoma

Triple checkpoint blockade - a new approach?

A new therapy benchmark for brain-met melanoma patients

TIL therapy for metastatic melanoma

Impactful studies from ASCO 24 III: Cell-therapy

Emerging rescue therapies for PD1 refractory melanoma

Identifying patients with longterm benefits during…

No differences in PFS between the two study arms

Survival data for TT with dabrafenib and trametinib

Lentigo maligna therapy

Neoadjuvant intratumoral therapy with Daromun in…

Intralesional therapy with Daromun

Neoadjuvant immunotherapy treatment for melanoma

A new triplet for metastatic melanoma

New oncolytic immunotherapy (RP1) after PD-1 failure

Prometedora actividad de brenetafusp en melanoma…

Consolidación del uso de IO en melanoma en estadio III…

No hubo diferencias en la PFS entre los dos brazos del…

New therapeutic approaches: Get over PD1 resistances?

New MOA in r/m HNSCC

New perspectives in HPV+ r/m HNSCC

New idea: anti-digest for EC?

De-escalation in ovarian cancer?